MedMarket DILIGENCE

Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2003-2013

PUBLISHED AUGUST 2003

• 338 pages • 32 Exhibits • 176 Company Profiles • Pub. Date Aug. 2003 • Report #S505

This report examines the status of technologies, applications and markets for tissue engineering, cell therapy and transplantation. The report reviews therapeutic technologies under various stages of development at over 150 companies. Products being developed address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, skin, organ and others. The report details the status of product development and assesses the current and forecast market for tissue engineering and transplantation products.

EXECUTIVE SUMMARY

SECTION 1: INTRODUCTION

1.1 Overview
1.2 Definitions
1.3 History of Tissue Reconstruction and Engineering
1.4 Growth of Key Procedures
1.5 Evolution of Tissue Processing Corporations
1.6 Regulatory Controls Shaping the Industry
1.7 Tissue Engineering as a Solution
1.8 Development Challenges
1.8.1 Material Based Tissue Replacements
1.8.2 Allograft Derived Tissue Replacements
1.8.3 Cell and Tissue Engineered Products
1.9 Market Expectations for Tissue Reconstruction and Engineering
1.9.1 Material Based Tissue Replacements
1.9.2 Allograft Tissue Replacements
1.9.3 Cell and Tissue Engineered Replacements
1.10 Unmet Clinical Need
1.11 Developing Tissue-Engineered Products
1.11.1 Culturing Cells
1.11.2 Cell Delivery
1.11.3 Bioengineering Cells and Tissues
1.12 Autologous, Allogeneic, and Xenogeneic Products
1.13 Timescales
1.14 Sector Challenges
1.15 Regulatory, Cost Effectiveness and Clinical
1.15.1 Regulatory
1.15.2 Cost Effectiveness
1.15.3 Clinical
1.16 Competition Intensity
1.16.1 Industry Focus
1.16.2 Investment Levels
1.16.3 Investor Returns

SECTION 2: CLINICAL CASELOAD

2.1 Overview
2.2 Cardiovascular Tissue Transplantation and Engineering
2.2.1 Introduction
2.2.2 Coronary Heart Disease
2.2.3 Myocardial Infarction
2.2.4 Congestive Heart Failure
2.2.5 Dysfunctional Heart Valves
2.2.6 Peripheral Vascular Disorders
2.2.7 Abdominal Aortic Aneurysms
2.2.8 Drivers of Caseloads for Cardiac Tissue Engineering
2.3 Neurological Tissue Transplantation and Engineering
2.3.1 Introduction
2.3.2 Stroke
2.3.3 Parkinson's
2.3.4 Alzheimer's
2.3.5 Epilepsy
2.3.6 Traumatic Injury
2.3.7 Peripheral Nerve Treatment
2.3.8 Multiple Sclerosis
2.3.9 Neurology Drivers
2.4 Orthopedic Tissue Transplantation and Engineering
2.4.1 Introduction
2.4.2 Cartilage Repair
2.4.3 Ligament Damage
2.4.4 Other Joints
2.4.5 Bone Graft Materials
2.4.6 Vertebral Disc Repair
2.4.7 Drivers of Orthopedic Tissue Engineering
2.5 Urological Tissue Transplantation and Engineering
2.5.1 Introduction
2.5.2 Incontinence
2.5.3 Drivers of Urological Tissue Engineering
2.6 Skin Tissue Transplantation and Engineering
2.6.1 Introduction
2.6.2 Burns
2.6.3 Diabetic Ulcers
2.6.4 Venous Ulcers
2.6.5 Plastic Surgery
2.7 Organ Transplantation and Engineering
2.7.1 Introduction
2.7.2 Liver Disease
2.7.3 Kidney
2.7.4 Pancreas
2.7.5 Intestinal Tissue Engineering
2.7.6 Hematopoietic Tissue Engineering
2.7.7 Drivers of Organ Replacement Tissue Engineering

SECTION 3: TECHNOLOGIES, PRODUCTS AND MARKETS

3.1 Overview
3.2 Cardiovascular
3.3 Neurological
3.4 Orthopedic
3.5 Urological
3.6 Skin Cell Engineering
3.7 Hematopoietic
3.8 Organ Reconstruction and Replacement
3.9 Potential for 'Tissue Engineering' Reconstruction

SECTION 4: COMPANY PROFILES

3DM Inc., Aastrom Bioscience Inc., Advanced Medical Solutions PLC, Acorda Therapeutics Inc., Advanced Cell Technology, Advanced Tissue Sciences Inc., Alexion Pharmaceuticals, Algenix Inc., Ariad Pharmaceuticals Inc.,

Artecel, Inc., Arthrex Inc., Anthrogenesis Inc. (Celgene Corporation), Avax Technologies Inc., Aventis, Baxter International Inc., BeFutur Biotechnologies, Biocomposites, Biocoral Inc., Biovascular Inc. (Synovis Life Technologies Inc.), Bioheart Inc., Biolife Solutions Inc., Biomet, Inc., BioMimetic Pharmaceuticals, Bionx Implants, Inc. (CONMED Corporation), BioNova International, BioTissue Technologies, Biotransplant Inc., Biohybrid Technologies, Biosyntech, Breonics, Bresagen Inc., Cambrex Bioproducts, Cardiotech International Inc., Celgene Corporation, Cell Based Delivery Inc., Cell Genesys Inc., Cell Pathways, Inc., Cell Science Therapeutics Inc., Cell Trends Inc., Cellect Bio Inc., CellExSys Inc., CellFactors Ltd, Cell-Lining GmbH, CellTran Ltd, Celmed BioSciences Inc. (Theratechnologies), Chrysalis BioTechnolology, Inc., Circe Biomedical Inc., co.don AG, Cook Group, CorCell, Inc., CRYO-CELL International, Inc., CryoLife, Inc., Clinical Cell Culture (C3), Curis Inc., Cytomatrix LLC, Cytograft Tissue Engineering, Dendreon Corporation, Dentigenix, Inc., Diacrin Inc., Durect Corporation, Encelle Inc., E.S. Cell International Pte Ltd, Enact Pharma PLC, Exactech, Inc., Excorp Medical, Inc., FibroGen, Inc., Fidia Advanced Biomaterials, Gamida–Cell Ltd, Genetix Ltd, Genetix Pharmaceuticals Inc., Genta, Inc., Genzyme Biosurgery, Genzyme Molecular Oncology, Geron Corporation, GHO Pharma, Immerge Biotherapeutics, Immunicon Corporation, Incara Pharmaceuticals, Inion Ltd, Innogenetics (Xcellentis), Instrument Makar Inc., Integra Life Sciences Inc., Interface Biologics Inc., Intermountain Organ Recovery Service, Interpore Cross International Inc., IsoTis NV, Isto Technologies Inc., Islet Sheet Medical, Islet Technology, Inc., Ixion Biotechnology Inc., Johnson and Johnson Inc. (Ethicon, DePuy, Mitek), Kensey Nash, Keratec, Kourion Therapeutics AG, Layton Biosciences Inc., Lifebank Inc., Lifecell Inc., Life Medical Sciences Inc., Linvatec Corporation Inc., Macropore Biosurgery Inc., MaxCyte, MeGA Tech GmbH, Microislet Inc., Millenium Biologix Inc., Modex Therapeutics, Mojave Therapeutics, MorphoGen Pharmaceuticals Inc., Morphogenesis Inc., Musculoskeletal Transplant Foundation, NanoMatrix Inc., Nephros Therapeutics Inc., NeuralStem Biopharmaceuticals Inc, NeuroNova AB, Neuronyx Inc., Neurotech SA and Neurotech U.S. Inc., Nexell Therapies, Novocell Inc., Onux Medical Inc., Organ Recovery Systems, Ortec International Inc., Organogenesis Inc., Orthovita, Osiris Therapeutics Inc., Osteobiologics, Osteotech, Polyganics Ltd, Poly-Med, Inc., PPL Therapeutics Ltd, Protein Polymer Technologies Inc., Progenitor Cell Therapy Inc., ProNeuron Biotechnologies, Inc., Regen Biologics Inc., Regeneration Technologies Inc., Renaissance Cell Technologies, RegenRx Pharmaceuticals, ReNeuron Ltd, Revivicor, Inc., Scaffix International, Sciperio Inc., Select Therapeutics Inc., Selective Genetics, Sertoli Technologies Inc., Smith and Nephew Ltd, Spiration Inc., Stem Cells Inc., Stem Cell Pharmaceuticals Inc., Stem Cell Sciences Ltd UK, Stem Cell Sciences Ltd, StemCell Technologies Inc., StemSource Inc., Surgical Dynamics Inc., Synovis Life Technologies, Inc., SyStemix, Inc., Targeted Genetics Inc., TEI Biosciences Inc., Tepha Inc., Theratechnologies Inc., Therics Inc., TiGenix N.V., Tissue Transformation Technologies Inc., TheraCyte Inc., TissueMed Ltd, Tissue Therapeutics, Inc., Titan Pharmaceuticals Inc., TolerRx, Inc., Transition Therapeutics Inc, Triage Medical Inc., Tristem Corporation, Verigen, ViaCell, Inc., VitaGen, Inc., Vitrolife AB, VivoRx, Xcyte Therapies, Inc., XCELLentis, Xylos Corporation

APPENDIX: LIST OF COMPANIES

List of Exhibits

Exhibit 1-1: Corporate Involvement in Tissue Transplantation and Engineering
Exhibit 1-2: Worldwide Market for Material Based Tissue Reconstruction Products, 2001–2013
Exhibit 1-3: Select Companies Developing Materials Applicable to Material-Based Tissue Reconstruction
Exhibit 1-4: Worldwide Sales of Tissue Engineered Products, 2002
Exhibit 1-5: Worldwide Sales of Donor Tissue Products, 2001-2013
Exhibit 1-6: Worldwide Market for Tissue Engineered Products, 2001–2013
Exhibit 1-7: Timescales for Development of Tissue Engineered Products
Exhibit 1-8: Clinical Development and Approvals (U.S.)
Exhibit 1-9: Examples of Tissue Engineering Strategies
Exhibit 1-10: Annual Revenues from Cell-Based Tissue Engineering Ventures in 2002
Exhibit 2-1: Potential For Cardiovascular Tissue Engineering — Incidences of Applicable Surgical Procedures, 2002
Exhibit 2-2: Potential for Neurological Tissue Engineering — Incidences of Applicable Procedures, 2002
Exhibit 2-3: Potential for Orthopedic Tissue Engineering — Incidence of Applicable Procedures, 2002
Exhibit 2-4: Potential for Urological Tissue Engineering — Incidence of Applicable Procedures, 2002
Exhibit 2-5: Potential for Dermal Tissue Engineering — Incidence of Applicable Procedures, 2002
Exhibit 2-6: Potential for Organ Tissue Engineering — Incidence of Applicable Procedures, 2002
Exhibit 3-1: Cardiovascular Cell Engineering Companies — Timescales
Exhibit 3-2: Key Developments for Cardiovascular Repair
Exhibit 3-3: Neurological Cell Engineering Companies — Timescales
Exhibit 3-4: Key Developments in Neurological Repair
Exhibit 3-5: Orthopedic Cell Engineering Companies — Timescales
Exhibit 3-6: Key Developments in Orthopedic Repair
Exhibit 3-7: Urology Cell Engineering Companies — Timescales
Exhibit 3-8: Key Developments in Urological Tissue Engineering
Exhibit 3-9: Skin Cell Engineering Companies — Timescales
Exhibit 3-10: Key Developments in Skin Tissue Engineering
Exhibit 3-11: Hematopoietic Cell Engineering Companies - Timescales
Exhibit 3-12: Key Developments in Hematopoietic Tissue Engineering
Exhibit 3-13: Organ Cell Engineering Companies — Timescales
Exhibit 3-14: Key Developments in Organ Tissue Engineering
Exhibit 3-15: Worldwide Market for Tissue Engineered Products, 2001–2013

To purchase, complete the form below and mail or fax to: ***MedMarket Diligence***, 51 Fairfield, Foothill Ranch, CA 92610
Tel: (949) 859-3401 **Fax: (949) 859-3487**. You may also order online at **www.mediligence.com**.

Name:_____

Title: _____

Company: _____

Address: _____

City: _____ State/Province: _____ ZIP-Postal:_____ Country: _____

Phone: _____ Fax: _____ Email: _____

Please send me report S505: "Tissue Engineering, Cell Therapy and Transplantation, 2003-2013"
for ☐ **$1,950** print/PDF (circle one) or ☐ **$2,150** print and PDF.

☐ Enclosed is my check* ☐ Invoice my company (PO#_____)

Charge my: ☐ Visa ☐ MasterCard ☐ American Express

Name on Card _____Signature_____

Card number_____Expiration date _____

*Make checks payable to *MedMarket Diligence*